Clinical efficacy analysis of risperidone in adjuvant treatment of depression

Objective: To explore efficacy and safety of risperidone combined with antidepressants in treatment of depression.Methods: 60 patients with depression were randomly divided into study group and the control group. The study group was treated with risperidone on the basis of the original antidepressant for 8 weeks,whereas the control group continued to use the original antidepressant treatment for 8 weeks. The Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA),Treatment Emergent Symptom Scale(TESS) were used to assess the efficacy and safety before and 2,4,6 and 8 weeks after the treatment. Results: The HAMD scores of the two groups significantly decreased after the treatment,but the efficacy of study group was better than that of control group,and there was a significant difference(t=2. 2882,t=2. 3095 P0. 05). The HAMA scores of the two groups significantly decreased after the treatment,but the efficacy of study group was better than that of control group,and there was a significant difference(t=3.3097,P0. 01). Moreover,study group is rapid in the efficacy,and the difference of the side effects of the two groups was not significant. Conclusions: The efficacy of Risperidone combined with paroxetine in the treatment of depression is superior than that of paroxetine. Study group is rapid in the efficacy,and the improvement of anxiety symptoms for the study group is better than that of the control group. So it is an effective and relatively safe method through risperidone combined with antidepressants to treat depression.